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I.

Abstract:

Hepatocellular carcinoma (HCC) is the most common type of liver cancer in the world.
Effective therapy options are limited; sorafenib is currently the only FDA-approved medication
for the disease. In order improve clinical prognoses, alternative treatment options must be
assessed and their mechanisms of action elucidated. An important hallmark of cancer is the
deregulation of normal cellular energetics, resulting in a number of crucial metabolic adaptations
to promote excessive proliferation. These changes include: the upregulation of aerobic glycolysis
(the “Warburg Effect”), coordinate over-expression of the tertiary nutrient transporter system
ASCT2 and LAT1, and enhanced glutamine uptake to support biosynthesis and stimulate growth
signaling. It is important to discover, understand, and exploit the metabolic differences between
normal and cancerous hepatocytes in order to develop successful therapies for HCC.
This project is comprised of three objectives: (1) to assess the efficacy and effective median
dosage of a multitude of metabolic inhibitors on a panel of epithelial and mesenchymal-derived
HCC cell lines, (2) to determine the growth impact of depriving SK-Hep-1-derived shRNAmediated ASCT2 and LAT1 knockdown cell lines of glutamine, and finally (3) to quantify the
expression of ASCT2 and LAT1 in cell lines under specific treatment conditions. These
objectives were accomplished through the combined usage of cell culture techniques,
proliferative assays, and western blot analysis. The most significant results include the effects of
metformin, a drug currently prescribed to patients with type 2 diabetes. The efficacy of
metformin in vitro was determined to be comparable to the FDA-approved medication sorafenib.
Metformin was also found to upregulate ASCT2 expression in both epithelial and mesenchymal
cell lines. Assessing the biochemical effects of metformin on HCC is necessary to answer a

critical question in cancer biology: how does metformin induce cell death in human
hepatocellular carcinoma?

II.

Introduction:
Human life expectancy is increasing, especially in modern times, due to a variety of

factors, including improved nutrition, sanitation, and medical advancements. Humanity has
effectively developed methods to manage and prevent severe diseases. While increasing life
expectancy has been a monumental development, it has also exposed an ancient disease: cancer.
Cancer is defined as a group of over 200 diseases that involve abnormal cellular growth and
proliferation, with the potential to metastasize to other tissues (NIH, 2015). In 2016, an estimated
1,685,210 cases of cancer will be diagnosed in the United States; consequently, approximately
595,690 people are predicted to succumb cancer. A startling 40% of men and women will be
diagnosed with cancer at some point in their lives (American Cancer Society, 2016). Cancer has
failed to gain prevalence until the last century because the disease manifests in aging.
Contributing to aging, the apparent incidence of cancer has increased substantially because of
improvements in screening techniques, such as mammography and PET-CT. Because of the
increasing frequency of cancer, the United States alone is expected to spend nearly $156 billion
in 2020 (NIH, 2016). Current treatment methods for cancer include surgery, chemotherapy, and
radiation. Depending on the individual, these options can be quite effective. However, there are
potentially substantial side effects to these treatments. Select chemotherapies and radiation have
an inherent risk of producing highly drug-resistant neoplasms in the affected tissue after
treatment. Another problem with chemotherapy and radiation is that for some cancers, the
therapies do little except to shortly extend the lifespan of the patient. Because of these issues, it

is crucial for research to be dedicated to understanding the mechanisms by which a cancer
manifests and persists in the face of aggressive treatment regimens. This effort will eventually
result in an era of personalized medicine, where a plethora of treatments are available and
utilized based on an individual genetic assessment of the cancer.
Hepatocellular Carcinoma (HCC), the most common type of liver cancer, is the third
leading cause of cancer mortality worldwide. It is the fourth most common cancer in the world,
and in North America the incidence is approximately two people out of every 100,000, whereas
in China, the incidence is higher at a rate of eighty people per 100,000 (Altekruse et al, 2009).
While the United States has a much lower incidence compared to areas of Asia and sub-Saharan
Africa, the prevalence has been increasing. In 2015, roughly 25,000 people in the United States
died from HCC (American Cancer Society, 2016). In most cases, HCC is a secondary
manifestation following liver cirrhosis, wherein the liver has been damaged to the point of losing
functionality. This process causes dramatic genetic and epigenetic changes in hepatocytes, which
can potentially result in a cancerous phenotype. Liver cirrhosis can be caused from alcohol
abuse, autoimmune diseases, viral hepatitis B or C, long term inflammation, and
hemochromatosis (El-Serag et al, 2007). In the United States, 30% to 40% of HCC is the result
of chronic hepatitis B or C (Caselmann, 1996). The available treatment options for HCC are
limited; currently there is only one FDA-approved chemotherapy for the disease: sorafenib. This
treatment is only moderately effective in hampering HCC progression. Because of the lack of
treatment options, research has been largely concentrated on elucidating the metabolic
differences between normal and cancerous hepatocytes in order to identify potential therapeutic
targets.

A hallmark of cancer is the deregulation of normal cellular energetics (Weinberg et al,
2011). The purpose of this deregulation is to support excessive growth and proliferation. The
functionality of various intracellular signaling pathways and enzymes have been altered in HCC
cells as a result. Previous research indicates that HCC cells have a higher capacity to take up the
amino acid glutamine from the extracellular environment, primarily through the plasma
membrane amino acid transporter ASCT2 (SLC1A5) (Wise et al, 2010). Glutamine is being
utilized for two purposes: the synthesis of metabolic precursors and intermediates required for
cellular proliferation, and the LAT1-coupled transport of leucine. Glutamine has the highest
blood plasma concentration of any amino acid because it is the primary carrier of nitrogenous
functional groups in the blood. These nitrogenous groups are incorporated into the synthesis of
immense quantities of nucleotides and proteins required for cancerous proliferation. Glutamine
can also be used to synthesize other amino acids and α-ketoglutarate, an important, bidirectional
TCA cycle intermediate (Nelson et al, 2012). ASCT2 is found to be significantly over-expressed
in a variety of epithelial cancers, and is thought to be the fundamental mediator of increased
glutamine uptake in these cancers (Bode et al, 2002). ASCT2 is a sodium-dependent, neutral
amino acid transporter which utilizes the sodium concentration gradient to energetically couple
the import of certain amino acids into the cell, including glutamine and asparagine. The mere
presence of glutamine has been linked to the overexpression of SLC1A5, the gene sequence for
the ASCT2 transporter (Brasse-Lagnel et al, 2009). The gene for the LAT1 transporter, SLC7A5,
is also over-expressed in HCC. LAT1 is a sodium-independent transporter that uptakes large,
branched, neutral amino acids, particularly leucine (Qiang et al, 2013). An important function of
LAT1 is utilizing intracellular glutamine to uptake leucine via an exchange mechanism. The

overexpression of both of these amino acid transporters contributes greatly to the increased
influx of glutamine and leucine into the cell.

Figure 1. ASCT2 and LAT1 tertiary amino acid transporter system. Bracketed amino
acids are transported by both ASCT2 and LAT1 (Image: Paige Bothwell).

While both glutamine and leucine are important for biosynthesis, these amino acids serve
another role in HCC cells: sustained activation of mTOR growth signaling. The mTORC1
signaling protein, an acronym for mammalian target of rapamycin complex one, is a crucial
serine/threonine kinase component of cell signaling implicated in both adjusting growth rates to
nutrient availability and inhibiting autophagy (Villanueva et al, 2008). Leucine, transported by
LAT1, is the primary stimulator of mTORC1 (Stipanuk, 2007). High intracellular glutamine
concentrations have been shown to activate mTORC1 signaling, albeit through a different
mechanism than leucine (Fumarola et al, 2005). ASCT2 and LAT1 are classified as a tertiary

transporter system because the ASCT2-imported glutamine is utilized by LAT1 to uptake
leucine, which subsequently activates mTORC1 (Bode et al, 2005). Some of the downstream
targets of mTORC1 signaling include the transcription and subsequent translation of proteins
involved in ribosome biogenesis, nutrient transport, and the inhibition of autophagy (Nicklin et
al, 2009). The activation of translational machinery, enhanced nutrient import for biosynthesis,
and downregulation of protein turnover greatly enhances HCC cell survival.

Figure 2. The complexity of mTOR growth signaling (Image:
http://www.novusbio.com/mTOR-pathway).

Within a tumor, areas become nutrient-deprived due to the lack of an adequate blood supply.
This is primarily a result of restricted blood vessel circulation due to intra-tumoral cell density,

termed the necrotic center. Limited vascularization leads to very low oxygen concentrations, a
hypoxic environment, and hypoxia induces the expression of a transcription factor known as
hypoxia-inducible factor-1 α (HIF-1α). HIF-1α has many transcriptional targets including
vascular endothelial growth factor (VEGF). VEGF is responsible for a variety of growth signals
including angiogenesis, the development of blood vessels. A common characteristic of HCC is to
constitutively activate HIF-1α, sustaining growth signaling (Moon et al, 2003). In addition to
limiting the oxygen supply, limited vascularization in dense regions of a tumor constrains the
delivery of glutamine via the blood stream. In such cases, cancerous tissue will upregulate
glutamine synthetase (GLUL) to produce glutamine from glutamate, ammonia, and ATP. In fact,
GLUL is shown to be overexpressed in HCC, particularly under the previously described
hypoxic conditions (Kuramitsu et al, 2006). These are two clever mechanisms HCC can evolve
to promote desired signaling and maintain intracellular glutamine concentrations.
Another critical metabolic difference between HCC and normal hepatocytes is the significant
upregulation of glycolysis, the first ATP-yielding step converting sugar to energy. Normally,
hepatocytes acquire most of their ATP through oxidative phosphorylation. The uncoupling of
glycolysis from oxygen tension, despite the efficiency of oxidative catabolism, is known as the
“Warburg effect” (Heiden et al, 2009). The hypoxic environment in the tumor, coupled with
beneficial VEGF signaling, selects for cells that can thrive on means other than oxygen through a
Darwinian mechanism. The purpose of the transition is not for energy generation, but to exploit
the pentose-phosphate shunt and other feeder pathways of glycolysis and the TCA cycle to
produce metabolic precursors.

Figure 3. Cancer metabolism in contrast to normal metabolism. Enhanced glucose uptake and
upregulated glycolysis results in the accumulation of lactate, a byproduct that is subsequently
expelled from the cell, acidifying the extracellular environment (Image:
http://www.sabiosciences.com/pathwaymagazine/minireview/metareprogram.php).

While HCC and other cancers acquire these characteristics to sustain proliferative capacity,
there are a number of important defense mechanisms established as well. One of these
mechanisms is the over expression of glutathione (GSH), a crucial protein complex whose role is
to eliminate reactive oxygen species produced by the cell. Interestingly, GSH also provides drug
resistance by binding chemotherapies and facilitating their expulsion from the cell (Batist et al,
1986). Altered metabolism coupled with defensive capabilities fortifies the ability of HCC to
survive and persist within the body. The purpose of describing these key biochemical changes is
to provide background for the various pathways targeted for therapeutic effectiveness in this
project. The following table displays the names, concentrations, and functions of the treatments
used:

Treatment
2-Deoxy-D
glucose (2DG)

Concentration
0.6 mM

Cobalt chloride
(CoCl2)

0.3 mM

Buthionine
sulfoximine
(BSO)

0.5 mM

3Bromopyruvate
(3BP)

0.05 mM

Metformin

10 mM

Rapamycin

20 nM

Sorafenib

10 uM

GPNA

1 mM

MeAIB

5 mM

BCH

5 mM

Mechanism
Glycolytic inhibitor - competitive inhibition of hexokinase function (Wick, A., Drury, D., Nakada, H., &
Wolfe, J. (1956). Localization of the Primary Metabolic Block Produced by 2-deoxyglucose. Journal of
Biological Chemistry, 963-969. Retrieved April 30, 2016, from http://www.jbc.org/)
Chemical inducer of hypoxia (specific reaction mechanism unknown) – ROS generation in signaling
independent of mitochondrial activity induces of HIF-1α transcription (as opposed to the traditional
hypoxic response, which is mitochondria-dependent activation of HIF-1α) (Bell, E., Klimova, T.,
Eisenbart, J., Schumacker, P., & Chandel, N. (2007). Mitochondrial Reactive Oxygen Species Trigger
Hypoxia-Inducible Factor-Dependent Extension of the Replicative Life Span during Hypoxia. Molecular
and Cell Biology, (16), 5737-5745. doi:10.1128/MCB.02265-06)
Glutathione biosynthetic inhibitor– inhibits γ-glutamylcysteinesynthetase (catalyzes the following: Lglutamate + L-cysteine + ATP gamma-glutamyl cysteine + ADP + Pi) (Griffith, O. (1982). Mechanism
of Action, Metabolism, and Toxicity of Buthionine Sulfoximine and Its Higher Homologs, Potent
Inhibitors of Glutathione Synthesis. Journal of Biological Chemistry, 257(22), 13704-13712. Retrieved
April 30, 2016, from http://www.jbc.org/)
Glycolytic inhibitor – inhibits glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity by
covalent pyruvylation of GAPDH (Ganapathy-Kanniappan, S., Geschwind, J., Kunjithapatham, R., &
Buijis, M. (2009). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3bromopyruvate mediated cancer cell death. Anticancer Research, 29(12), 4909-4918. Retrieved April 30,
2016, from http://ar.iiarjournals.org/)
Gluconeogenic inhibitor (specific reaction mechanism unknown) – inhibits mitochondrial ETC complex
I and mitochondrial glycerol-phosphate dehydrogenase (mGPD); both actions induce energetic stress and
elevate the AMP:ATP ratio leading to activation of AMPK and glycolysis, and inhibition of
gluconeogenesis (via both an AMPK-dependent mechanism and a cAMP-dependent mechanism)
(Luengo, A., Sullivan, L., & Vander Heiden, M. (2014). Understanding the complex-I-ty of metformin
action: Limiting mitochondrial respiration to improve cancer therapy. BioMed Central Biology, 12(82).
doi:10.1186/s12915-014-0082-4)
Protein synthesis inhibitor – inhibits mTORCI through blocking RAPTOR; mTORCI is a serine
threonine kinase responsible for controlling cell growth, proliferation, and survival (Ballou, L., & Lin, R.
(2008). Rapamycin and mTOR Kinase Inhibitors. Journal of Biological Chemistry, 1(4), 27-36.
doi:10.1007/s12154-008-0003-5)
Cell proliferation/angiogenesis inhibitor – inhibits RAF/MEK/ERK pathway and tyrosine kinases
VEGFR/PDGFR, responsible for angiogenesis for the tumor cell conglomerate (Adnane, L., Trail, P.,
Taylor, I., & Wilhelm, S. (2006). Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets
RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Methods in Enzymology, 407, 597-612. Retrieved April 30, 2016, from
http://www.sciencedirect.com/science/journal/00766879)
Neutral amino acid uptake inhibitor specific to system ASC– SLC1A5 (ASCT2) inhibitor which inhibits
glutamine uptake into the cancer cell and furthermore inhibiting glutamine dependent mTOR activation
(Wise, D. R., & Thompson, C. B. (2010). Glutamine Addiction: A New Therapeutic Target in Cancer. Cell,
35(8), 427-433. Retrieved April 19, 2016, from http://www.cell.com/)
Neutral amino acid uptake inhibitor specific to system A – system A (sodium dependent neutral
amino acid transport) inhibitor which inhibits uptake capacity of various system A nutrient transporters
critical for supporting excessive growth (Wise, D. R., & Thompson, C. B. (2010). Glutamine Addiction:
A New Therapeutic Target in Cancer. Cell, 35(8), 427-433. Retrieved April 19, 2016, from
http://www.cell.com/)
Large heterodimeric amino acid transport inhibitor specific to system L – inhibits system L amino
acid transporters (LAT1), inducing apoptosis through intracellular depletion of amino acids essential for
cancer growth (Kim, C., Cho, S., Chun, H., Lee, S., Endou, H., Kanai, Y., & Kim, D. (2008). BCH, an
inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biological and
Pharmaceutical Bulletin, 31(6), 1096-1100. Retrieved April 30, 2016, from
https://www.jstage.jst.go.jp/browse/bpb)

Table 1: Names, concentrations, and functions of the inhibitors used throughout the project.
Metformin, a drug used for modulating blood glucose levels in patients with type II diabetes, is
of particular interest. Epidemiological research indicates the incidence of various cancers
decreases in patients prescribed metformin; however, the mechanism of growth inhibition and
cell death is unknown.

III.

Methodology:

Cell Lines and Treatments:
Epithelial and mesenchymal-derived HCC cell lines were utilized throughout the
experiments. Epithelial cell lines include: Huh1, Huh7, HepG2, Hep3B, and P5. Mesenchymal
cell lines include: Focus, 2237, 2238, 2234, SK-Hep1, and 2236. SK-Hep1 LAT1 and ASCT2
knockdown cell lines were also used; they were generated by Dr. Barrie Bode’s doctoral student
Paige Bothwell using a lentiviral vector encoding several specific short hairpin RNAs (shRNA)
targeting the mRNA transcripts of ASCT2 and LAT1. Puromycin resistance and Green
Fluorescent Protein (GFP) were indicators of successful plasmid integration. Cell lines were
maintained at 37°C in a humidified atmosphere of 5% CO2-95% air in Dulbecco’s Modified
Eagle Medium (DMEM, 4.5 mg/ml D-glucose) supplemented with 10% triple 0.1 μm filtered
fetal bovine serum (FBS), 2 mM L-glutamine, 1% antibiotic/anti-mycotic solution (100x stock:
10,000 U/ml Penicillin G, 10,000 μg/ml Streptomycin, and 25 μg/ml Amphotericin). The culture
vessels used include 25 cm2 Falcon T-flasks with 0.2 μm vented blue plug seal caps, 100mm
plates, 12-well plates, and 48-well plates. All cell count measurements in this study were
performed using a hemacytometer. Treatments were filter-sterilized to prevent bacterial
contamination.

Figure 4. Mesenchymal HCC cell line SK-Hep1, imaged on EVOSTM.

MTT Cell Proliferation Assay:
The MTT cell proliferation assay is a colorimetric, metabolic assay utilized to determine
cell number. The concept is that the quantity of oxidoreductase enzymes in a well will be
proportional to the number of cells; these enzymes reduce tetrazolium dye to formazan, a purple
crystal (Fig 5.). After treatments were completed, the tetrazolium dye solution was added to the
wells and incubated to promote the enzymatic reaction. Next, the plates were dumped and the
formazan was solubilized using a 0.04 N HCl solution in absolute isopropanol. Absorbance data
was collected from the spectrophotometer and exported to Microsoft Excel to be displayed
graphically.

Figure 5. After solubilizing formazan crystals, cell number can be qualitatively assessed based
on the purple hue; however, this is assuming the number of oxidoreductase enzymes are
consistent between cells (Image: http://www.iivs.org/scientific-services/laboratoryservices/ocular-irritation/human-3d-tissue/step-by-step/).

TaliTM Image-Based Cytometer:
In contrast to the MTT assay, the TaliTM Image-Based Cytometer counts the cells
directly. This eliminates a confounding variable: assuming the number of oxidoreductase
enzymes is consistent between cells. Cells were washed in phosphate buffered saline (PBS),
TrypLE, an enzymatic solution for dissociating adherent cells from a growth surface, and then
suspended in supplemented DMEM. Cells were subsequently loaded into capillary plates and
examined using the TaliTM Image-Based Cytometer and associated programming. Data was
exported to Microsoft Excel to be displayed graphically.

SDS-PAGE:
Extracted protein lysate concentration was measured using the Nanodrop 2000TM
Spectrophotometer. After determining protein concentrations, 20 µg of each protein sample was
prepared using 1 M dithiothreitol (DTT), 4x sample Laemmli buffer (LSB), and 1x lysis buffer.
Samples were subsequently denatured and separated via sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) at 150 V for 45 minutes. The electrical field generated in the
gel allows denatured proteins to separate based on molecular weight. Biotinylated protein ladder
and three color molecular weight marker were also loaded; they are used to confirm protein band
location.

Western Blotting:
Before SDS-PAGE was completed, 1x transfer buffer was prepared and refrigerated.
PVDF membranes were equilibrated for fifteen seconds in methanol, two minutes in nanopure
water, and five minutes in 1X transfer buffer. After SDS-PAGE was completed, the gels were
removed and incubated in transfer buffer for ten minutes. A transfer “sandwich” was then
constructed and ran at 75V for 90 minutes (Fig 6.). Ice surrounds the rig to lower the
temperature, facilitating a successful transfer. Afterwards, the western blots were hung to dry for
one hour. After drying, the blots were incubated in blocking buffer composed of 5% bovine
serum albumin (BSA) in tris-buffered saline and 1% tween (TBST) for one hour. This is to
prevent non-specific binding between the antibody and PVDF membrane instead of the intended
protein. After the blocking step, the membranes were further incubated in the primary antibody
of interest for twelve hours. The primary antibody specificity depends on the protein of interest;

antibodies can also be monoclonal or polyclonal. The blots were then washed 3 times for 5
minutes in TBST. After the washes, the blots were incubated in anti-rabbit, HRP-conjugated
secondary antibody for one hour. The secondary antibody binds specifically to the primary
antibody used in the previous step (Fig 7.)

Figure 6. Western blot setup, including the contents of the “sandwich” (Image:
http://www.antikoerper-online.de/resources/17/1224/Western+Blot+Hintergrundinformationen/).

Membrane Imaging:
After three, five minute washes in TBST, membranes were incubated for one minute in
Lumiglo chemiluminescent substrate. Lumiglo is comprised of luminol and horseradish
peroxidase (HRP), where the luminol is converted to an intermediate dianion in the presence of

hydrogen peroxide. This dianion emits light when reverting to its ground state energy stability,
which can be captured on x-ray film using Genesnap software. The membrane was then reprobed for a particular loading control depending on the protein of interest.

Figure 7. Western blot and imaging mechanism (Image:
http://info.gbiosciences.com/blog/bid/159273/Which-Blocking-Agent-for-Western-Blotting).

Protein Quantification:
In order to quantify and normalize protein quantities to the loading controls used, Image-J
and Microsoft Excel software was utilized. The ratio of black pixels in the bands can be
compared and displayed in a bar graph, providing a quantitative and normalized representation of
the results.

IV.

Results:

Graph 1. Epithelial HCC cell lines HepG2, Hep3B, Huh1, Huh7, P5, and Tong under the
treatment conditions of metformin, sorafenib, rapamycin, GPNA, MeAIB, and BCH. MTT
proliferation assays were performed at 24, 48, 72, and 96 hours. DMSO was used as a vehicle
control for sorafenib and rapamycin. The x-axis represents time while the y-axis is the ratio of
control absorbance.

Graph 2. Mesenchymal HCC cell lines SK-Hep1, Focus, 2234, 2236, 2237, 2238, and Mahlavu
under the treatment conditions of metformin, sorafenib, rapamycin, GPNA, MeAIB, and BCH.
THLE5B is an immortalized hepatocyte cell line and MIA-PACA-2 is a pancreatic cancer cell
line. MTT proliferation assays were performed at 24, 48, 72, and 96 hours. DMSO was used as a
vehicle control for sorafenib and rapamycin. The x-axis represents time while the y-axis is the
ratio of control absorbance.

Graph 3. Mesenchymal HCC cell line SK-Hep1 treated with various concentrations of
buthionine sulfoximine, cobalt chloride, 2-deoxy-D-glucose, and 3-bromopyruvate. MTT
proliferation assays were performed after 72 hours in order to establish an ED50, which is the
median effective dosage of treatment. The estimated ED50’s are: 0.60 mM (2DG), 0.28 mM
(CoCl2), 0.07 mM (BSO), and 0.05 mM (3BP). The x-axis is treatment concentration and the yaxis is the absorbance measured.

Graph 4. SK-Hep1-derived ASCT2 (A2) and LAT1 (L1) knockdowns were incubated in
differing concentrations of the amino acid glutamine for 72 hours. Media was changed daily for
the “fed” cell lines, while the “un-fed” cell lines retained the same media from time zero. The
nonsense control refers to SK-Hep1 that was manipulated via RNAi; however, purposely no
knockdown is exhibited. The TaliTM image-based cytometer and MTT assay were performed at
the 72 hour time point and compared to determine differences between metabolic and
concentration centered growth assays. The x-axis is the differing glutamine concentrations, while
the y-axis is average absorbance for the MTT assay and cell concentration for the Tali TM imagebased cytometer.
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Figure 8. Mesenchymal HCC cell line SK-Hep1 was treated with normal media, vehicle control
(DMSO), sorafenib, rapamycin, metformin, and lactate for 24 hours (C, V, S, R, M, L labels
respectively). Lactate was used because it is a large byproduct of the “Warburg Effect”. The
images were derived from western blot analysis. Beta-actin and Cox IV were used as loading
controls for ASCT2 and LAT1 respectively. Protein quantification and normalization were
accomplished through Image-J software. The x-axis represents the different treatments and the yaxis is the ratio of the control protein quantity.
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Figure 9. Epithelial HCC cell line Hep3B was treated with normal media, vehicle control
(DMSO), sorafenib, rapamycin, metformin, and lactate for 24 hours (C, V, S, R, M, L labels
respectively). Lactate was used because it is a large byproduct of the “Warburg Effect”. The
images were derived from western blot analysis. Beta-actin and Cox IV were used as loading
controls for ASCT2 and LAT1 respectively. Protein quantification and normalization were
accomplished through Image-J software. The x-axis represents the different treatments and the yaxis is the ratio of the control protein quantity.

V.

Discussion

The MTT and cytometric analysis demonstrated that the treatments that were the most
successful in inhibiting cellular proliferation were sorafenib, rapamycin, and metformin (Graphs
1 & 2). Sorafenib’s efficacy was expected because it is currently the only FDA-approved
medication for HCC. Inhibition of the growth signaling pathways mediated by VEGFR/PDGFR
was certainly effective in vitro. Rapamycin, a drug commonly employed in transplant patients,
was also effective in many of the cell lines. Rapamycin inhibits mTORC1, the growth signaling
pathway stimulated by leucine. Remarkably, metformin was similarly as effective as sorafenib in
many of the cell lines. Metformin is a gluconeogenic inhibitor; this is a component of the
mechanism by which it modulates blood sugar concentrations. This may interfere with the
“Warburg Effect” described previously, preventing proliferation and causing cell death.
Metformin’s impact on growth appears to be more significant in the mesenchymal cell lines
versus the epithelial. Perhaps hampered gluconeogenesis affects aggressive cell lines more
because they require relatively more biosynthetic precursors than a slower, epithelial cell line.
Another inhibitor that worked moderately was GPNA; P5, HepG2, SK-Hep1, and Mahlavu were
all significantly affected. GPNA inhibits ASCT2, the transport protein responsible for the
upregulated influx of glutamine. Insufficient glutamine hampers the cells’ ability to proliferate
by limiting biosynthesis and indirect mTORC1 stimulation. This may suggest a greater
dependency on the glutamine uptake activity of ASCT2 for survival in these cell lines.
The next objective was determining the effective median doses of four inhibitors using
secondary HCC cell line SK-Hep1. The results were as follows: 0.60 mM (2DG), 0.28 mM
(CoCl2), 0.07 mM (BSO), and 0.05 mM (3BP) (Graph 3). Buthionine sulfoximine, 3bromopyruvate, and cobalt chloride were effective at significantly lower concentrations than 2-

deoxy-D-glucose. Buthionine sulfoximine inhibits glutathione synthesis, which would promote
the accumulation of reactive oxygen species. Reactive oxygen species can be beneficial to cancer
by increasing the incidence of mutation; however, reaching a critical threshold would render the
cell incapable of functioning and stimulate apoptosis. Inhibition of glycolysis by 3bromopyruvate prevents utilization of the “Warburg Effect” to drive growth. Cobalt chloride
effectiveness is interesting because it induces a hypoxic response. Hypoxia typically stimulates
HIF1-α, which is pro-growth. The mechanism of action is unknown; other effects could be the
cause of the growth inhibition.
Glutamine is a significant player in the stimulation of growth signaling; its availability in
the extracellular environment differentially affects the growth of the ASCT2 knockdown cell line
versus the nonsense control. The results from the glutamine dilution study indicate that when
media is not changed daily over 72 hours, at every glutamine concentration the ASCT2
knockdown cell line exhibits decreased proliferation (Graph 4). Since ASCT2 is the primary
channel for glutamine influx, reduced ASCT2 expression may manifest in a slower proliferative
phenotype. The second, side objective of this particular study was to compare cell growth data
received from the MTT assay to the data obtained via the TaliTM Image-Based Cytometer. Both
results appear to be quite similar; however, the TaliTM Image-Based Cytometer provides other
morphological characteristics of the cells, such as size, and eliminates a confounding variable:
the number of oxidoreductase enzymes between cells. This variable appears to be constant from
this experiment, and the results from both the MTT and cytometric assays are in accord.
The final study assessed the protein expression of ASCT2 and LAT1 in SK-Hep1 and
Hep3B under the treatment conditions of sorafenib, rapamycin, metformin, and lactate. The most
significant result concerns metformin: ASCT2 expression is higher in both the primary and

secondary HCC cell lines (Figures 8 & 9). Upregulation of ASCT2 may be a stress response to
the induction of oxidative metabolism. However, further experimentation must be completed to
accurately assess metformin’s mechanism of action. Another interesting result is that lactate
stimulated down-regulation of ASCT2 in SK-Hep1. Since lactate is acidifying the extracellular
environment, this decrease in pH may trigger hypoxic responses in the cell. This response may
involve downregulating the expression of ASCT2 because there is no purpose to having a
transporter for something that is absent in the extracellular environment.
The greatest obstacle in treating cancer is that the molecular and physiological functions
utilized by normal cells and tissues are commandeered and exploited; how does one specifically
target biochemical signatures that are utilized by the 100 trillion other healthy cells in the human
body? Despite this inherent dilemma, novel chemotherapies are being developed constantly to
target critical differences that manifest from cancerous transformation. This project was a small
step towards assessing the importance of glutamine, ASCT2, LAT1, and the effectiveness of
multiple inhibitors on human hepatocellular carcinoma, a cancer that bears dismal prognoses due
to the lack of viable therapies. Although cancer incidence is surging, the awareness of this
disease is also growing. This increased awareness is manifesting in the development of effective,
specialized treatments that have the potential to make lethal cancer a relic of the past.
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